NU-Verap en es it fr

NU-Verap Brand names, NU-Verap Analogs

NU-Verap Brand Names Mixture

  • Tarka (trandolapril + verapamil hydrochloride)

NU-Verap Chemical_Formula

C27H38N2O4

NU-Verap RX_link

http://www.rxlist.com/cgi/generic/verapsr.htm

NU-Verap fda sheet

NU-Verap FDA

NU-Verap msds (material safety sheet)

NU-Verap Synthesis Reference

Dengel, U.S. Pat. 3,261,859 (1966)

NU-Verap Molecular Weight

454.602 g/mol

NU-Verap Melting Point

< 25 oC

NU-Verap H2O Solubility

4.47 mg/L

NU-Verap State

Liquid

NU-Verap LogP

5.931

NU-Verap Dosage Forms

Capsule (sustained-release); Liquid; Solution; Tablet; Tablet (extended-release)

NU-Verap Indication

For the treatment of hypertension and angina.

NU-Verap Pharmacology

Verapamil, a class IV antiarrhythmic agent, is used as a calcium-channel blocking (CCB) agent for the treatment of angina, hypertension, and for supraventricular tachyarrhythmias.

NU-Verap Absorption

90%

NU-Verap side effects and Toxicity

LD50=8 mg/kg (i.v. in mice)

NU-Verap Patient Information

Verapamil HCl is known as a calcium channel blocker. It is taken to treat high blood pressure, to relieve some chest pains in patients with angina, or to treat some problems with heart rhythms. Verapamil has several drug interactions, make sure your physician and pharmacist known all the medicines you are taking so they may properly advise you. Verapamil HCl is excreted in breast milk. It may be necessary to change therapy or provide an alternate to breast milk. The most common side effect is constipation. This may be relieved with dietary modification (more fiber) or laxatives. Sustained release tablets should be taken with food. They should not be broken or crushed. Doses may need some adjustment, make sure to have your condition monitored regularly.

NU-Verap Organisms Affected

Humans and other mammals